Patent intelligence · US
US 10786512
DNA-PK inhibitors
DNA-PK inhibitors
Patent details — US 10786512
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 29, 2020
- Expiration
- Sep 24, 2040
- Applicant
- Vertex Pharmaceuticals Incorporated
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/5386
Quick answer
US 10786512 (DNA-PK inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Sep 29, 2020. Expires Sep 24, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Vertex Pharmaceuticals Incorporated
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K31/506, A61K31/5377, A61K31/5386, A61P, A61P35/00
More from Vertex Pharmaceuticals Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12421249
Inhibitors of APOL1 and methods of using same
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12384762
Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
granted -
US 12385013
Differentiation of pancreatic endocrine cells
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12371665
Differentiation of pancreatic endocrine cells
granted -
US 12350262
Methods of treatment for cystic fibrosis
granted
Frequently asked questions
What is US patent 10786512?
US 10786512 (DNA-PK inhibitors) is held by Vertex Pharmaceuticals Incorporated. Status: granted. Granted Sep 29, 2020. Expires Sep 24, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10786512?
Vertex Pharmaceuticals Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 991 pharmaceutical patents for this assignee.
When does US 10786512 expire?
Our index shows an expiration date of Sep 24, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.